|
English
|
正體中文
|
简体中文
|
總筆數 :0
|
|
造訪人次 :
51246407
線上人數 :
595
教育部委託研究計畫 計畫執行:國立臺灣大學圖書館
|
|
|
"jih hsiang lee"的相關文件
顯示項目 31-37 / 37 (共1頁)
1
每頁顯示[10|25|50]項目
| 臺大學術典藏 |
2022-02-21T03:52:32Z |
A phase I study of pexidartinib, a colony-stimulating factor 1 receptor inhibitor, in Asian patients with advanced solid tumors
|
JIH-HSIANG LEE; Chen T.W.-W.; Hsu C.-H.; Yen Y.-H.; Yang J.C.-H.; Cheng A.-L.; Sasaki S.-I.; Chiu L.Y.; Sugihara M.; Ishizuka T.; Oguma T.; Tajima N.; Lin C.-C. |
| 臺大學術典藏 |
2022-02-21T03:52:32Z |
Association between programmed death-ligand 1 expression, immune microenvironments, and clinical outcomes in epidermal growth factor receptor mutant lung adenocarcinoma patients treated with tyrosine kinase inhibitors
|
Yang C.-Y.; Liao W.-Y.; Ho C.-C.; Chen K.-Y.; Tsai T.-H.; Hsu C.-L.; Su K.-Y.; Chang Y.-L.; Wu C.-T.; Hsu C.-C.; Liao B.-C.; Hsu W.-H.; JIH-HSIANG LEE; Lin C.-C.; Shih J.-Y.; Yang J.C.-H.; Yu C.-J. |
| 臺大學術典藏 |
2022-02-21T03:52:31Z |
Two first-in-human studies of xentuzumab, a humanised insulin-like growth factor (IGF)-neutralising antibody, in patients with advanced solid tumours
|
de Bono J.; Lin C.-C.; Chen L.-T.; Corral J.; Michalarea V.; Rihawi K.; Ong M.; JIH-HSIANG LEE; Hsu C.-H.; Yang J.C.-H.; Shiah H.-S.; Yen C.-J.; Anthoney A.; Jove M.; Buschke S.; Fuertig R.; Schmid U.; Goeldner R.-G.; Strelkowa N.; Huang D.C.-L.; Bogenrieder T.; Twelves C.; Cheng A.-L. |
| 臺大學術典藏 |
2022-02-21T03:52:31Z |
Association of Programmed Death-Ligand 1 Expression with Fusion Variants and Clinical Outcomes in Patients with Anaplastic Lymphoma Kinase-Positive Lung Adenocarcinoma Receiving Crizotinib
|
Yang C.-Y.; Liao W.-Y.; Ho C.-C.; Chen K.-Y.; Tsai T.-H.; Hsu C.-L.; Liu Y.-N.; Su K.-Y.; Chang Y.-L.; Wu C.-T.; Liao B.-C.; Hsu C.-C.; Hsu W.-H.; JIH-HSIANG LEE; Lin C.-C.; Shih J.-Y.; Yang J.C.-H.; Yu C.-J. |
| 臺大學術典藏 |
2022-02-21T03:52:30Z |
Serial Plasma Cell-Free Circulating Tumor DNA Tests Identify Genomic Alterations for Early Prediction of Osimertinib Treatment Outcome in EGFR T790M�VPositive NSCLC
|
Liao B.-C.; Hsu W.-H.; JIH-HSIANG LEE; Yang C.-Y.; Tsai T.-H.; Liao W.-Y.; Ho C.-C.; Lin C.-C.; Shih J.-Y.; Yu C.-J.; Soo R.A.; Yang J.C.-H. |
| 臺大學術典藏 |
2020-04-08T10:35:55Z |
Association between programmed death-ligand 1 expression, immune microenvironments, and clinical outcomes in epidermal growth factor receptor mutant lung adenocarcinoma patients treated with tyrosine kinase inhibitors
|
Chia-Chi Hsu; Bin-Chi Liao; Wei-Hsun Hsu; Jih-Hsiang Lee; Chia-Chi Lin; Jin-Yuan Shih; James C.-H. Yang; Chong-Jen Yu; Ching-Yao Yang; Wei-Yu Liao; Chao-Chi Ho; Kuan-Yu Chen; Tzu-Hsiu Tsai; Chia-Lin Hsu; Kang-Yi Su; Yih-Leong Chang; Chen-Tu Wu; Chong-Jen Yu;James C.-H. Yang;Jin-Yuan Shih;Chia-Chi Lin;Jih-Hsiang Lee;Wei-Hsun Hsu;Bin-Chi Liao;Chia-Chi Hsu;Chen-Tu Wu;Yih-Leong Chang;Kang-Yi Su;Chia-Lin Hsu;Tzu-Hsiu Tsai;Kuan-Yu Chen;Chao-Chi Ho;Wei-Yu Liao;Ching-Yao Yang |
| 臺大學術典藏 |
2020-04-08T10:35:55Z |
Association between programmed death-ligand 1 expression, immune microenvironments, and clinical outcomes in epidermal growth factor receptor mutant lung adenocarcinoma patients treated with tyrosine kinase inhibitors
|
Chia-Chi Hsu; Bin-Chi Liao; Wei-Hsun Hsu; Jih-Hsiang Lee; Chia-Chi Lin; Jin-Yuan Shih; James C.-H. Yang; Chong-Jen Yu; Ching-Yao Yang; Wei-Yu Liao; Chao-Chi Ho; Kuan-Yu Chen; Tzu-Hsiu Tsai; Chia-Lin Hsu; Kang-Yi Su; Yih-Leong Chang; Chen-Tu Wu; Chong-Jen Yu;James C.-H. Yang;Jin-Yuan Shih;Chia-Chi Lin;Jih-Hsiang Lee;Wei-Hsun Hsu;Bin-Chi Liao;Chia-Chi Hsu;Chen-Tu Wu;Yih-Leong Chang;Kang-Yi Su;Chia-Lin Hsu;Tzu-Hsiu Tsai;Kuan-Yu Chen;Chao-Chi Ho;Wei-Yu Liao;Ching-Yao Yang |
顯示項目 31-37 / 37 (共1頁)
1
每頁顯示[10|25|50]項目
|
